Steven A. Toms, MD

Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses the combination of the Novo Tumor Treating Fields (NovoTTF) system and temozolomide for patients with glioblastoma.

Patients were randomized 2:1 to NovoTTF in combination with temozolomide (n = 210) or standard therapy (n = 105), which included surgery, radiation, and temozolomide.

Progression-free and overall survival were both enhanced with the addition of NovoTTF.

Anecdotally, Toms said, NovoTTF has been well-tolerated by patients.

Steven A. Toms, MD | Authors

Articles

NovoTTF and Temozolomide for Glioblastoma